Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01081678
Registration number
NCT01081678
Ethics application status
Date submitted
4/03/2010
Date registered
5/03/2010
Date last updated
21/09/2022
Titles & IDs
Public title
Study To Assess FRacTure Healing With SclerosTin Antibody - Hip
Query!
Scientific title
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults With a Fresh Unilateral Hip Fracture, Status Post Surgical Fixation
Query!
Secondary ID [1]
0
0
20080394
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
STARTT-Hip
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Fracture Healing
0
0
Query!
Condition category
Condition code
Injuries and Accidents
0
0
0
0
Query!
Fractures
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Romosozumab
Placebo Comparator: Placebo - Participants received placebo to romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
Experimental: Romosozumab 70 mg - Participants received 70 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
Experimental: Romosozumab 140 mg - Participants received 140 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
Experimental: Romosozumab 210 mg - Participants received 210 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
Treatment: Drugs: Placebo
Administered by subcutaneous (under the skin) injection
Treatment: Drugs: Romosozumab
Administered by subcutaneous injection
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Timed-Up-and-Go (TUG) Over Week 6 Through Week 20
Query!
Assessment method [1]
0
0
Functional healing was measured by the timed-up-and-go test (TUG) over Weeks 6 through 20. During this assessment, the clinician timed the participant while they stood up from a seated position in a chair, walked three meters, turned around, walked three meters back to the chair, and returned to the seated position. A TUG value of ten seconds or less was considered normal for a healthy elderly person. Higher TUG values after hip fracture have been shown to be a predictor of future falls.
Least squares mean (LSM) estimates were based on a repeated measures model fitted with the log-transformed TUG values at weeks 2, 6, 12, 16, 20, 24, 36, 52 as the dependent variable and adjusted for treatment, randomized strata, gender, country category, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction and back-transformed using the exponential transformation.
Query!
Timepoint [1]
0
0
Weeks 6, 12, 16, and 20
Query!
Secondary outcome [1]
0
0
Timed-Up-and-Go (TUG) at Each Visit
Query!
Assessment method [1]
0
0
During the timed-up-and-go test the clinician timed the participant while they stood up from a seated position in a chair, walked 3 meters, turned around, walked 3 meters back to the chair, and returned to a seated position. A TUG value of = 10 seconds is considered normal for a healthy elderly person.
LSMs were based on a repeated measures model adjusting for treatment, randomized strata, gender, country category, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction.
Missing TUG values for participants still on study were imputed using the last observation carried forward (LOCF) when possible. If no observation could be carried forward, the maximum TUG value observed among all participants at a given visit was used. TUG values obtained after unplanned revision surgery were replaced by carrying forward the last available observed or imputed value prior to unplanned revision surgery.
Query!
Timepoint [1]
0
0
Weeks 2, 6, 12, 16, 20, 24, 36, and 52
Query!
Secondary outcome [2]
0
0
Time to Radiographic Healing
Query!
Assessment method [2]
0
0
Time to radiographic healing is the time interval from the surgery date for the eligible hip fracture to the date of radiographic healing, defined as effacement of the fracture lines by newly formed bone along the cortices and within the trabecular bone on anteroposterior and lateral (or oblique) radiographs. Radiographic fracture healing was determined by a panel of independent reviewers blinded to treatment.
The cumulative incidence function (CIF) method was used to estimate the median time to radiographic healing and the confidence intervals. Unplanned revision surgery to promote healing was considered a competing risk in CIF estimate.
Query!
Timepoint [2]
0
0
52 weeks
Query!
Secondary outcome [3]
0
0
Radiographic Union Scale for Hip (RUSH) Score At Each Visit
Query!
Assessment method [3]
0
0
The radiographic Union Scale for Hip (RUSH) is a semiquantitative scoring assessment to assess hip fracture healing after surgical repair. The RUSH has 4 key domains based on radiographic parameters used by orthopedic surgeons and radiologists in routine clinical practice including cortical bridging (4 to 12 points), cortical fracture line disappearance (4 to 12 points), trabecular consolidation (1 to 3 points), and trabecular index disappearance of fracture line (1 to 3 points). The score has a minimum of 10 points (definitely not healed) and a maximum of 30 points (definitely healed).
Query!
Timepoint [3]
0
0
Weeks 2, 6, 12, 16, 20, 24, 36, and 52
Query!
Secondary outcome [4]
0
0
Harris Hip Score At Each Visit
Query!
Assessment method [4]
0
0
The Harris Hip Score is a clinician-based outcome that assesses pain, function, deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities and gait. Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. The score ranges form 0-100 (best possible outcome) covering pain (0-44 points), function (0-47 points), absence of deformity (4 points), and range of motion (5 points). LSMs were based on a repeated measures model fitted with the Harris hip score values at weeks 2, 6, 12, 16, 20, 24, 36, and 52 as the dependent variable and adjusted for treatment, randomized strata, gender, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction.
Query!
Timepoint [4]
0
0
Weeks 2, 6, 12, 16, 20, 24, 36, and 52
Query!
Secondary outcome [5]
0
0
Hip Pain Score at Each Visit
Query!
Assessment method [5]
0
0
Hip pain was assessed using a visual analog scale (VAS). Participants were asked to rate their pain as a result of the hip fracture on a 100 mm vertical scale with 0 indicating no pain at all and 100 indicating the worst pain they could imagine.
LSMs were based on a repeated measures model fitted with hip pain score values at weeks 2, 6, 12, 16, 20, 24, 36, and 52 as the dependent variable and adjusted for treatment, randomized strata, gender, pre-fracture community-dwelling status, pre-fracture walking aid use, quality of surgical fixation, visit, and treatment-by-visit interaction.
Query!
Timepoint [5]
0
0
Weeks 2, 6, 12, 16, 20, 24, 36, and 52
Query!
Eligibility
Key inclusion criteria
- Males and females, age 55 to 95 years
- fresh unilateral low energy intertrochanteric or femoral neck fracture as the primary
injury, confirmed by X-ray and in the opinion of the treating surgeon amenable to
repair by internal fixation
- internal fixation of the fracture with devices approved by local regulatory agency,
performed no later than 7 days after injury for intertrochanteric or undisplaced
femoral neck fractures and no later than 2 days after injury for displaced femoral
neck fractures
- intertrochanteric fracture: sliding hip screw or IM nail
- femoral neck fracture: sliding hip screw or at least 3 cancellous screws
Query!
Minimum age
55
Years
Query!
Query!
Maximum age
95
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- severe symptomatic osteoarthritis of the lower extremity
- inability to independently rise from armchair or walk 200 meters before hip fracture
- presence of concomitant injuries such as rib fractures, wrist fractures, or acute
symptomatic vertebral fractures which severely impair the ability to rise from a chair
- associated extremity injuries including ipsilateral or contralateral fractures of the
foot, tibia or fibula, wrist, humerus, femoral shaft, femoral head or hip dislocation,
that may delay weight-bearing beyond one week after surgery
- head-injury, as defined by Glasgow Coma Scale < 13 prior to randomization
- use of bone grafts or bone substitutes at the time of fracture fixation
- major polytrauma or significant axial trauma, with Injury Severity Score > 16
- pathological fracture or history of metabolic or bone disease (except osteoporosis)
that may interfere with the interpretation of the results, such as Paget's disease,
rheumatoid arthritis, osteomalacia, osteopetrosis, ankylosing spondylitis, Cushing's
disease, hyperprolactinemia
- history of symptomatic spinal stenosis that has not been surgically corrected. If
surgically corrected, the subject must be asymptomatic to be eligible for the study.
- history of facial nerve paralysis
- malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma,
cervical carcinoma in situ) within the last 5 years
- history of solid organ or bone marrow transplants
- evidence of elevated transaminases (= 2.0 x upper limits of normal) or significantly
impaired renal function (creatinine clearance of = 30 mL/min)
- evidence of current hypercalcemia or hypocalcemia (outside of 1.1 x the normal range)
- bone morphogenic proteins (BMP)-2 or BMP-7 at the time of definitive fracture fixation
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
20/06/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
10/05/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
332
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Research Site - Liverpool
Query!
Recruitment hospital [2]
0
0
Research Site - Footscray
Query!
Recruitment postcode(s) [1]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [2]
0
0
3011 - Footscray
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Indiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Minnesota
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
Argentina
Query!
State/province [9]
0
0
Buenos Aires
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Brugge
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Genk
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Leuven
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Liege
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Liège
Query!
Country [15]
0
0
Bulgaria
Query!
State/province [15]
0
0
Blagoevgrad
Query!
Country [16]
0
0
Bulgaria
Query!
State/province [16]
0
0
Pleven
Query!
Country [17]
0
0
Bulgaria
Query!
State/province [17]
0
0
Plovdiv
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Alberta
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Ontario
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Quebec
Query!
Country [21]
0
0
Denmark
Query!
State/province [21]
0
0
Hvidovre
Query!
Country [22]
0
0
Denmark
Query!
State/province [22]
0
0
København NV
Query!
Country [23]
0
0
Denmark
Query!
State/province [23]
0
0
Viborg
Query!
Country [24]
0
0
Denmark
Query!
State/province [24]
0
0
Ã…rhus C
Query!
Country [25]
0
0
Estonia
Query!
State/province [25]
0
0
Tallinn
Query!
Country [26]
0
0
Estonia
Query!
State/province [26]
0
0
Tartu
Query!
Country [27]
0
0
Finland
Query!
State/province [27]
0
0
Kuopio
Query!
Country [28]
0
0
Finland
Query!
State/province [28]
0
0
Oulu
Query!
Country [29]
0
0
Finland
Query!
State/province [29]
0
0
Turku
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Aachen
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Berlin
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Muenchen
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Muenster
Query!
Country [34]
0
0
Greece
Query!
State/province [34]
0
0
Athens
Query!
Country [35]
0
0
Greece
Query!
State/province [35]
0
0
Larissa
Query!
Country [36]
0
0
Greece
Query!
State/province [36]
0
0
Patra
Query!
Country [37]
0
0
Greece
Query!
State/province [37]
0
0
Thessaloniki
Query!
Country [38]
0
0
Hong Kong
Query!
State/province [38]
0
0
Hong Kong
Query!
Country [39]
0
0
Hong Kong
Query!
State/province [39]
0
0
New Territories
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Budapest
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Miskolc
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Nyiregyhaza
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Szeged
Query!
Country [44]
0
0
India
Query!
State/province [44]
0
0
Andhra Pradesh
Query!
Country [45]
0
0
India
Query!
State/province [45]
0
0
Karnataka
Query!
Country [46]
0
0
India
Query!
State/province [46]
0
0
Maharashtra
Query!
Country [47]
0
0
India
Query!
State/province [47]
0
0
Rajasthan
Query!
Country [48]
0
0
India
Query!
State/province [48]
0
0
Mangalore
Query!
Country [49]
0
0
India
Query!
State/province [49]
0
0
Nashik
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Firenze
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Milano
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Roma (RM)
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Verona
Query!
Country [54]
0
0
Latvia
Query!
State/province [54]
0
0
Riga
Query!
Country [55]
0
0
Latvia
Query!
State/province [55]
0
0
Valmiera
Query!
Country [56]
0
0
Lithuania
Query!
State/province [56]
0
0
Kaunas
Query!
Country [57]
0
0
Lithuania
Query!
State/province [57]
0
0
Vilnius
Query!
Country [58]
0
0
Netherlands
Query!
State/province [58]
0
0
Amsterdam
Query!
Country [59]
0
0
Netherlands
Query!
State/province [59]
0
0
Haarlem
Query!
Country [60]
0
0
Netherlands
Query!
State/province [60]
0
0
Nieuwegein
Query!
Country [61]
0
0
New Zealand
Query!
State/province [61]
0
0
Christchurch
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Kraków
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Lublin
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Warszawa
Query!
Country [65]
0
0
Slovenia
Query!
State/province [65]
0
0
Celje
Query!
Country [66]
0
0
Slovenia
Query!
State/province [66]
0
0
Izola
Query!
Country [67]
0
0
Slovenia
Query!
State/province [67]
0
0
Jesenice
Query!
Country [68]
0
0
Slovenia
Query!
State/province [68]
0
0
Sempeter pri Gorici
Query!
Country [69]
0
0
Sweden
Query!
State/province [69]
0
0
Linköping
Query!
Country [70]
0
0
Sweden
Query!
State/province [70]
0
0
Lund
Query!
Country [71]
0
0
Switzerland
Query!
State/province [71]
0
0
Basel
Query!
Country [72]
0
0
Switzerland
Query!
State/province [72]
0
0
Lausanne
Query!
Country [73]
0
0
Switzerland
Query!
State/province [73]
0
0
Luzern
Query!
Country [74]
0
0
Switzerland
Query!
State/province [74]
0
0
Zurich
Query!
Country [75]
0
0
United Kingdom
Query!
State/province [75]
0
0
Barnet
Query!
Country [76]
0
0
United Kingdom
Query!
State/province [76]
0
0
Leeds
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
London
Query!
Country [78]
0
0
United Kingdom
Query!
State/province [78]
0
0
Newcastle
Query!
Country [79]
0
0
United Kingdom
Query!
State/province [79]
0
0
Norwich
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an international, multi-center study to determine the efficacy, safety, and
tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status
post surgical fixation.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01081678
Query!
Trial related presentations / publications
Schemitsch EH, Miclau T, Karachalios T, Nowak LL, Sancheti P, Poolman RW, Caminis J, Daizadeh N, Dent-Acosta RE, Egbuna O, Chines A, Maddox J, Grauer A, Bhandari M. A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures. J Bone Joint Surg Am. 2020 Apr 15;102(8):693-702. doi: 10.2106/JBJS.19.00790.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01081678
Download to PDF